Previous Close | 2.5600 |
Open | 2.4200 |
Bid | 2.3300 x 200 |
Ask | 2.3600 x 400 |
Day's Range | 2.3300 - 2.6000 |
52 Week Range | 1.0800 - 3.7900 |
Volume | |
Avg. Volume | 3,107,275 |
Market Cap | 153.189M |
Beta (5Y Monthly) | 1.55 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Financial and Clinical Progress Amidst Net Loss Wider Than Estimates
Amylyx Pharmaceuticals (AMLX) and Acadia Pharmaceuticals (ACAD) plunged on failure of studies.
Data from an early-stage study shows that treatment with Regulus' (RGLS) lead drug shows increased biological activity at a higher dose in patients with autosomal dominant polycystic kidney disease.